

treatment for recurrent or refractory PCNSL has been limited yet. In this study, we investigated clinical course of eight refractory or recurrent PCNSL cases treated with tirabrutinib in our institute.

Eight PCNSL cases treated with tirabrutinib included four recurrent cases and four refractory cases. Five cases obtained CR or PR after 26.8 days administration of tirabrutinib and other two cases also exhibited obvious improvement of clinical symptoms after 23.5 days administration of tirabrutinib. Among three cases exhibiting intraocular lesions, two cases revealed improvement of visual dysfunction and the other case obtained SD status of intraocular lesion. The most frequently found adverse effect was the skin rash. CTCAE grade 2 (n=2) or 3 (n=2) rash was found after mean 16 days or 94 days of tirabrutinib administration, respectively. Two cases with grade 3 rash could start taking the low-dose tirabrutinib after improvement of rash. Although one case experienced shingles, no other case experienced serious adverse effects.

Although adverse effect of rash was frequently found, we could obtain high response rate of tirabrutinib treatment for recurrent or refractory PCNSL cases. We need to establish quantitative assessment method for analysis of treatment response of tirabrutinib for intraocular lesions.

Key words: Tirabrutinib | PCNSL | Skin rash

ML-12

CLINICAL IMPACT AND MANAGEMENT OF SKIN-RELATED DISORDERS DURING TREATMENT OF RELAPSED PCNSL BY TIRABRUTINIB

Nobuyoshi Sasaki¹, Keiichi Kobayashi¹, Kuniaki Saito¹, Ryo Onoda¹, Yosuke Seiya¹, Saki Suzuki¹, Yuki Yamagishi^{2,3}, Hirofumi Nakatomi¹, Yoshiaki Shiokawa¹, Motosu Nagane¹; ¹Department of Neurosurgery, Kyorin University faculty of medicine, Tokyo, Japan ²Division of Brain Disease Translational Research, Juntendo University Faculty of Medicine, Tokyo, Japan ³Department of Neurosurgery, Kyorin University Graduate School of Medicine, Tokyo, Japan

BACKGROUNDS: Tirabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor, approved by the Japanese Pharmaceutical and Medical Devices Agency (PMDA) for relapsed and refractory PCNSL in March 2020. Skin-related disorder (SRD)s are the most prevalent adverse events in tirabrutinib, which accounted for 54.5% in a phase I/II trial. While the use of tirabrutinib is increasingly considered in clinical practice, the prevalence and clinical impact of tirabrutinib-related SRDs in real-world practice remains unclear. **METHODS:** Relapsed PCNSL patients treated with tirabrutinib at the author's institution were identified, and divided into those with SRDs (SRD group), and without SRDs (non-SRD group). Response rate and progression-free survival (PFS) were retrospectively analyzed and compared between the two groups. **RESULTS:** Eleven patients were identified (median age: 73 [range: 50–83], median KPS: 70 [range: 40–90]), which included six (54.5%) from the SRD group and five (45.5%) from the non-SRD group. Response rate was 100% in the SRD group and 60% in the non-SRD group. Median PFS was 2.8 months in the SRD group and 36.3 months in the non-SRD group, which yielded no significant difference (p=0.446). While antihistamine prophylaxis using fexofenadine was performed in seven patients, among them SRDs were observed in three (27.3%). SRDs lead to tirabrutinib interruption (for seven days or more) in two (18.2%), dose reduction in three (27.3%), and discontinuation in two (18.2%) patients. Four patients in whom tirabrutinib was interrupted or discontinued due to SRDs had shorter PFS, compared with the two patients from the SRD group in whom tirabrutinib was continued (median PFS: 2.3 and 29.6 months, respectively) (p=0.049). **CONCLUSIONS:** SRDs substantially lead to tirabrutinib interruption or discontinuation, which could result in early PD. Since fexofenadine prophylaxis seems ineffective for preventing SRDs, other antihistamines should be considered. Establishment of the optimal management of tirabrutinib-related SRDs is warranted.

Key words: PCNSL | tirabrutinib | Bruton's tyrosine kinase

ML-13

PRIMARY CENTRAL NERVOUS SYSTEM MALIGNANT LYMPHOMA IN A PATIENT WITH RHEUMATOID ARTHRITIS RECEIVING TOCILIZUMAB

Masasuke Ohno¹, Syunichiro Kuramitsu², Soyohei Ito², Masayuki Kimata², Takumi Asai², Noriyuki Suzuki², Yasukazu Kajita², Tastuo Takahashi²; ¹The Department of Neurosurgery, Aichi Cancer Center Hospital, Nagoya, Japan ²The Department of Neurosurgery, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

Background: Although the risk of developing malignant lymphoma is higher in patients with rheumatoid arthritis (RA) than in the general population, the occurrence of primary central nervous system lymphoma (PCNSL) in patients with RA is extremely rare. In recent years, there has been concern that biological disease-modifying antirheumatic drugs (DMARDs), which are widely administered to patients with RA, may in-

crease the risk of developing cancer. We report the first case of PCNSL in a patient with RA who was treated with the biological DMARDs, tocilizumab. **Case description:** A 70-year-old man, who was diagnosed with RA in 2010 was treated with low-dose methotrexate from 2010 to 2015. He was started on tocilizumab in 2012. In 2018, he suffered from gait disturbance and was diagnosed with lumbar spinal stenosis. He underwent L2/3 posterior fusion surgery, but his paraplegia gradually deteriorated. Two months after the surgery, a head Gd-MRI showed multiple contrast-enhanced lesions in the basal ganglia and brain stem. A stereotactic brain biopsy was performed and DLBCL was diagnosed, and finally PCNSL was diagnosed because of no neoplastic lesions in other organs. He was treated with 5 courses of MTX 3.5g/m² with rituximab and has been in remission for 23 months. He has maintained an independent life with residual paraplegia, but his ADLs gradually worsened. He was restarted on tocilizumab with a diagnosis of worsening RA. **Conclusion:** Low-dose methotrexate and biological DMARDs including tocilizumab, have been concerned to increase the risk of cancer in patients with RA, but there is no solid evidence. Since it has been a short time since the use of biological DMARDs, further accumulation of cases and careful follow-up are necessary.

Key words: Primary central nervous system lymphoma | Methotrexate | Tocilizumab

ML-16

FIRST CLINICAL EXPERIENCE OF ADMINISTRATION OF TIRABRUTINIB FOR THE PATIENTS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Sho Onodera¹, Jiro Akimoto¹; ¹Department of Neurosurgery, Kohsei Chuo General Hospital

Tirabrutinib (TIR), a Bruton's tyrosine kinase inhibitory drug, has been approved in Japan for treating relapsed/refractory primary central nervous system lymphoma (PCNSL). The authors recently encountered three patients with newly diagnosed refractory PCNSL using TIR.

Three patients, 48, 78 and 88 years-old males, diagnosed with PCNSL by histologically verification were firstly treated with high dose Methotrexate based chemotherapy (HD-MTX) and/or radiotherapy, however these cases were refractory for these standard treatments, demonstrated early cerebrospinal fluid dissemination or accompanied with severe adverse event. The authors decided to administrate TIR to these patients with a full informed consent. TIR demonstrated dramatic reduction of the volume of tumor on MRI within one month after administration of TIR, and improved the patient's performance status. However, one case demonstrated liver dysfunction and multiple brain abscess due to aspergillus infection, and one case demonstrated early progression of the tumor 49 days after starting TIR.

Administration of TIR for the patients with newly diagnosed refractory PCNSL demonstrated a rapid and dramatic clinical response, and presented with several clinical implications for this complicated condition.

Key words: Tirabrutinib | refractory primary central nervous system lymphoma | adverse event

ML-17

CLINICAL USEFULNESS OF TIRABRUTINIB IN RECURRENT PCNSL: SINGLE INSTITUTE EXPERIENCE.

Jun Matsuura¹, Jun-Ichiro Kuroda¹, Tatsuya Takezaki¹, Naoki Shinojima¹, Akitake Mukasa¹; ¹Department of Neurosurgery, University of Kumamoto, Kumamoto, Japan

Background: Primary central nervous system lymphoma (PCNSL) is a lymphoma whose primary lesion is localized in the brain and spinal cord. Treatment is a combination of high-dose methotrexate-based chemotherapy and whole-brain irradiation, often leading to recurrence. Pathologically, non-GCB type diffuse large B-cell lymphoma (DLBCL) predominates. In DLBCL, constitutive activation of B cell receptor signal (BCR) is the tumor mechanism of tumor development and growth. Tirabrutinib is an inhibitor of Bruton's tyrosine kinase (BTK) located downstream of BCR. In a phase I / II study, an overall response rate was 64%. Currently, Tirabrutinib is used to treat relapsed or refractory PCNSL. **Purpose:** Tirabrutinib is a drug that has just been approved, and there are few reports of its use in clinical practice. We report on our experience with Tirabrutinib with a review of the literature. **Methods:** We retrospectively examined the clinical course of 11 recurrent PCNSL patients treated with Tirabrutinib at our institution. **Results:** The average age of the subjects was 68.7 years, and 7 cases were male. Tirabrutinib 480 mg was administered in all cases. The response rate was 60% (6/10 cases). The median progression-free survival was 4.3 months. The adverse events were Grade 3 neutropenia in 1 patient and Grade 2 skin disorder in 4 patients. Treatment was discontinued in 5 of the 11 patients due to the progression of the disease. Due to the eruption, Tirabrutinib was reduced to 320 mg in 1 patient and discontinued in 1 patient. Treatment was discontinued at the request of the patient in 1 case, and four patients are still